Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014444 | 0.93 | NLRP3 (0.35) | NLRP3ROCK2LSSGSR | |
| SCHEMBL23692211 | 0.86 | ROCK2 (0.35) | NLRP3ROCK2LSS | |
| SCHEMBL25067179 | 0.85 | FASN (0.30) | NLRP3 | |
| SCHEMBL22014582 | 0.82 | NLRP3 (0.34) | NLRP3ROCK2LSSGSR | |
| SCHEMBL22014446 | 0.81 | NLRP3 (0.33) | NLRP3ROCK2LSSGSR | |
| SCHEMBL25139315 | 0.81 | NLRP3 (0.33) | NLRP3ROCK2LSSGSR | |
| SCHEMBL20698683 | 0.81 | NLRP3 (0.39) | NLRP3ROCK2LSSGSR | |
| SCHEMBL22014445 | 0.81 | NLRP3 (0.39) | NLRP3ROCK2LSSGSR | |
| SCHEMBL25067186 | 0.77 | NLRP3 (0.39) | NLRP3LSS | |
| SCHEMBL23668419 | 0.75 | NLRP3 (0.47) | NLRP3ROCK2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658538-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-16 | — | — | US | disclosed |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-06-28 | — | — | US | disclosed |
| US-20210230129-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019023145-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ROCK2 3165/4885LSS 1248/4885 |
| US-20210230129-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP3, NLRP1, IAPP | NLRP3 1/4885ROCK2 103/4885LSS 1119/4885 |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP3, NLRP1, IAPP | NLRP3 1/4885ROCK2 103/4885LSS 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.